Stocks
Applied Therapeutics Financial Statements (APLT) |
||||||||||
| Applied Therapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 13.03.2020 | 18.03.2021 | 10.03.2022 | 23.03.2023 | 06.03.2024 | 06.03.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.000 | 9.99 | 11.3 | |||
| Operating Income, bln rub | -45.6 | -94.5 | -105.6 | -83.0 | -64.5 | -64.5 | ||||
| EBITDA, bln rub | ? | -45.6 | -94.5 | -105.6 | -82.9 | -64.2 | -35.1 | |||
| Net profit, bln rub | ? | -45.4 | -93.0 | -104.6 | -81.7 | -119.8 | -119.0 | |||
| OCF, bln rub | ? | -36.3 | -78.2 | -90.7 | -78.1 | -55.2 | -55.2 | |||
| CAPEX, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||
| FCF, bln rub | ? | -36.3 | -78.2 | -90.7 | -78.1 | -55.2 | -55.2 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 45.6 | 94.5 | 105.6 | 83.0 | 74.2 | 74.5 | ||||
| Cost of production, bln rub | 0.023 | 0.380 | 0.415 | 0.441 | 0.353 | 0.694 | ||||
| R&D, bln rub | 32.4 | 61.8 | 62.6 | 55.6 | 53.9 | 53.9 | ||||
| Interest expenses, bln rub | 0.093 | 0.559 | 0.555 | 0.442 | 0.000 | 1.44 | ||||
| Assets, bln rub | 48.4 | 104.5 | 89.9 | 38.4 | 54.8 | 54.8 | ||||
| Net Assets, bln rub | ? | 32.6 | 81.9 | 62.5 | 4.06 | -17.1 | -17.1 | |||
| Debt, bln rub | 2.04 | 1.74 | 1.33 | 0.891 | 1.23 | 0.777 | ||||
| Cash, bln rub | 38.9 | 96.8 | 80.8 | 30.6 | 49.9 | 49.9 | ||||
| Net debt, bln rub | -36.8 | -95.1 | -79.5 | -29.7 | -48.7 | -49.1 | ||||
| Ordinary share price, rub | 27.3 | 22.0 | 8.95 | 0.760 | 3.35 | 2.30 | ||||
| Number of ordinary shares, mln | 12.8 | 22.0 | 25.6 | 37.8 | 84.2 | 84.2 | ||||
| Market cap, bln rub | 350 | 483 | 229 | 29 | 282 | 194 | ||||
| EV, bln rub | ? | 313 | 388 | 150 | -1 | 234 | 145 | |||
| Book value, bln rub | 33 | 82 | 63 | 4 | -17 | -17 | ||||
| EPS, rub | ? | -3.54 | -4.23 | -4.09 | -2.16 | -1.42 | -1.41 | |||
| FCF/share, rub | -2.83 | -3.56 | -3.54 | -2.06 | -0.65 | -0.65 | ||||
| BV/share, rub | 2.54 | 3.73 | 2.44 | 0.11 | -0.20 | -0.20 | ||||
| EBITDA margin, % | ? | -642.3% | -310.0% | |||||||
| Net margin, % | ? | -1 198% | -1 051% | |||||||
| FCF yield, % | ? | -10.4% | -16.2% | -39.6% | -271.7% | -19.5% | -28.5% | |||
| ROE, % | ? | -139.2% | -113.5% | -167.3% | -2 012% | 698.5% | 694.3% | |||
| ROA, % | ? | -93.8% | -89.0% | -116.4% | -212.9% | -218.4% | -217.1% | |||
| P/E | ? | -7.71 | -5.20 | -2.19 | -0.35 | -2.36 | -1.63 | |||
| P/FCF | -9.64 | -6.18 | -2.53 | -0.37 | -5.12 | -3.51 | ||||
| P/S | ? | 28.2 | 17.1 | |||||||
| P/BV | ? | 10.7 | 5.90 | 3.66 | 7.08 | -16.5 | -11.3 | |||
| EV/EBITDA | ? | -6.87 | -4.11 | -1.42 | 0.01 | -3.64 | -4.12 | |||
| Debt/EBITDA | 0.81 | 1.01 | 0.75 | 0.36 | 0.76 | 1.40 | ||||
| CAPEX/Revenue, % | 0.00% | 0 | ||||||||
| Applied Therapeutics shareholders | ||||||||||
